SLC5A2 and type 2 diabetes mellitus: This real-world evidence suggests that in patients with T2DM who were previously uncontrolled on a DPP4-i-based antihyperglycemic regimen and were SGLT2-i-naïve, use of the original FDC of empagliflozin and linagliptin may be associated with meaningful reductions in UACR levels and stabilization of the eGFR slope over 12 months.